In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia.

The topics covered include:

When to use cytoreduction therapies and which therapies to use in low-risk patients
Type 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reports
Experts’ thoughts on therapy options in higher-risk patients

Presenters:

Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Andrew Kuykendall, MD
Assistant Professor
Department of Oncologic Sciences
University of South Florida
Assistant Member
Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, Florida

Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.

Link to the full program, including downloadable slides and an on-demand webcast from the live event:
bit.ly/3XF3cSF

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Treatment Considerations for Patients With Essential Thrombocythemia: A Conversation Between Experts